136 related articles for article (PubMed ID: 11420466)
1. Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesis.
Southey MC; Young MA; Whitty J; Mifsud S; Keilar M; Mead L; Trute L; Aittomäki K; McLachlan SA; Debinski H; Venter DJ; Armes JE
Am J Surg Pathol; 2001 Jul; 25(7):936-41. PubMed ID: 11420466
[TBL] [Abstract][Full Text] [Related]
2. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test.
Mathiak M; Rütten A; Mangold E; Fischer HP; Ruzicka T; Friedl W; Propping P; Kruse R
Am J Surg Pathol; 2002 Mar; 26(3):338-43. PubMed ID: 11859205
[TBL] [Abstract][Full Text] [Related]
3. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families.
Ponti G; Ponz de Leon M; Losi L; Di Gregorio C; Benatti P; Pedroni M; Scarselli A; Riegler G; Lembo L; Pellacani G; Seidenari S; Rossi G; Roncucci L
Br J Dermatol; 2005 Jun; 152(6):1335-8. PubMed ID: 15949004
[TBL] [Abstract][Full Text] [Related]
4. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
5. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
6. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
7. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
8. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome.
Machin P; Catasus L; Pons C; Muñoz J; Conde-Zurita JM; Balmaña J; Barnadas M; Martí RM; Prat J; Matias-Guiu X
J Cutan Pathol; 2002 Aug; 29(7):415-20. PubMed ID: 12139636
[TBL] [Abstract][Full Text] [Related]
9. Cystic sebaceous tumors as marker lesions for the Muir-Torre syndrome: a histopathologic and molecular genetic study.
Rütten A; Burgdorf W; Hügel H; Kutzner H; Hosseiny-Malayeri HR; Friedl W; Propping P; Kruse R
Am J Dermatopathol; 1999 Oct; 21(5):405-13. PubMed ID: 10535567
[TBL] [Abstract][Full Text] [Related]
10. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
11. Is the mismatch repair deficient type of Muir-Torre syndrome confined to mutations in the hMSH2 gene?
Kruse R; Lamberti C; Wang Y; Ruelfs C; Bruns A; Esche C; Lehmann P; Ruzicka T; Rütten A; Friedl W; Propping P
Hum Genet; 1996 Dec; 98(6):747-50. PubMed ID: 8931714
[TBL] [Abstract][Full Text] [Related]
12. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
13. A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene.
Vernez M; Hutter P; Monnerat C; Halkic N; Gugerli O; Bouzourene H
Fam Cancer; 2007; 6(1):141-5. PubMed ID: 17051350
[TBL] [Abstract][Full Text] [Related]
14. [Mutation in the MSH2 gene in Muir-Torre syndrome].
Godard V; Coulet F; Bernaudin JF; Housset M; Soubrier F
Ann Dermatol Venereol; 1999; 126(8-9):600-3. PubMed ID: 10530347
[TBL] [Abstract][Full Text] [Related]
15. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].
Czakó L; Tiszlavicz L; Takács R; Baradnay G; Lonovics J; Cserni G; Závodná K; Bartosova Z
Orv Hetil; 2005 May; 146(20):1009-16. PubMed ID: 15945244
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
17. [Muir-Torre syndrome].
Körber J; Djawari D
Hautarzt; 2001 Dec; 52(12):1107-10. PubMed ID: 11910863
[TBL] [Abstract][Full Text] [Related]
18. Widespread microsatellite instability in sebaceous tumours of patients with the Muir-Torre syndrome.
Peris K; Onorati MT; Keller G; Magrini F; Donati P; Muscardin L; Höfler H; Chimenti S
Br J Dermatol; 1997 Sep; 137(3):356-60. PubMed ID: 9349329
[TBL] [Abstract][Full Text] [Related]
19. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
Chhibber V; Dresser K; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
[TBL] [Abstract][Full Text] [Related]
20. [Muir-Torre syndrome].
Jonas J; Kruse R; Bähr R
Chirurg; 2002 Apr; 73(4):366-9. PubMed ID: 12063922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
